Sign up
Pharma Capital

ReNeuron makes key business development hire as it looks to build on licensing deals

ReNeuron Group PLC's (LON:RENE) Michael Hunt caught up with Proactive London's Andrew Scott following the news this morning that they've appointed a business development director, Nick Adams,  to help them build on the licence deals signed with Chinese giant Fosun Pharma.

Hunt also discusses the recent release of their preliminary results covering the 12 months to the end of March 2019.

One of the year's highlights came in February, when they reported positive initial data from the mid-stage study of its retinitis pigmentosa treatment.

 

View full RENE profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.